Whalesbook
Alivus Life Sciences Reports Strong Q3FY26 Driven by Margin Expansion and CDMO Revival
Alivus Life Sciences Limited experienced a positive market reaction, with its shares advancing following the release of its December quarter (Q3FY26) financial results. The company posted a healthy increase in profitability and revenue, underscoring a strategic shift towards higher-margin segments and operational efficiencies.
Revenue and Margin Expansion Fuel Performance
The company's top line grew to ₹672.9 crore in Q3FY26, an increase from ₹641.8 crore in the corresponding quarter of the previous year. This revenue growth was underpinned by contributions from both its core Active Pharmaceutical Ingredient (API) business and a resurgent Contract Development and Manufacturing Organisation (CDMO) segment. Generic API revenue saw a modest 1.7% year-on-year rise, alongside a 11.1% quarter-on-quarter increase. More significantly, the CDMO business demonstrated robust recovery, reporting a substantial 100% quarter-on-quarter growth and an 85.3% year-on-year expansion, attributed to strong traction in existing projects and new product launches. Profit After Tax (PAT) rose by 9.7% year-on-year to ₹150.3 crore. However, the most striking improvement was observed in profitability metrics, with Earnings Before Interest, Tax, Depreciation, and Amortisation (EBITDA) reaching ₹245.2 crore, up from ₹200.8 crore a year prior. This translated into a record EBITDA margin of 36.4%, a significant jump from 31.3% in the same period last year, signaling enhanced operational efficiency and pricing power.
Financial Fortitude and Strategic Investments
Alivus Life Sciences maintained its strong financial footing, operating as a net debt-free company. For the first nine months of FY26, the company generated free cash flow of ₹220.7 crore, reinforcing its financial flexibility. As of December 31, 2025, its cash and cash equivalents stood at a robust ₹733 crore. Despite this strong liquidity, the company has revised its capital expenditure guidance downwards to approximately ₹450 crore for FY26, deferring about ₹150 crore to FY27. While brownfield expansions at Ankleshwar and Dahej are progressing, the Solapur facility commissioning has been delayed by approximately three months, now expected by July 2026. The company targets a capacity utilisation of 85-90% post-expansion.
Industry Context and Competitive Positioning
Alivus Life Sciences operates within India's rapidly growing pharmaceutical sector, which is projected to expand by 9-11% in FY2026. The API market itself is a substantial global industry, estimated at USD 245.67 billion in 2026, with Asia-Pacific being the fastest-growing region. The company's peers in the API manufacturing space include major players like Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Aurobindo Pharma, and Divi's Laboratories. Alivus Life Sciences, formerly Glenmark Life Sciences, leverages its expertise in chronic therapeutic areas such as cardiovascular, central nervous system, pain management, and diabetes, while increasingly focusing on CDMO services for multinational clients. The company's competitive edge is bolstered by its 595 Drug Master File (DMF) and Certificate of Suitability (CEP) filings across major global markets as of December 31, 2025.
Future Projections and Outlook
Analysts have placed a target price of ₹1,297.33 on Alivus Life Sciences, suggesting an upside potential of 51%. The company has upgraded its full-year margin guidance to 30–32%, indicating confidence in sustained profitability driven by a favourable product mix, CDMO recovery, and ongoing operational efficiencies. With its strong financial position, diversified revenue streams, and a strategic focus on high-value segments, Alivus Life Sciences is positioned to navigate the evolving pharmaceutical landscape, although the overall market faces pressures from moderating growth in the US generics market and increasing regulatory scrutiny.